Hypercholesterolaemia is a characteristic of nephrotic syndrome that likely contributes to the increased cardiovascular risk associated with the disease; however, therapies to reduce cholesterol ...

DelveInsight's PCSK9 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, ...

Quick lipid lowering did not translate to clinical benefit at 1 year ...

Starting evolocumab in the cath lab before PCI did not, however, result in better clinical outcomes in the first year.

Lipfendra, approved by the US FDA, is the world's first oral PCSK9 inhibitor pill. It reduces bad cholesterol by up to 60%.

A structure-guided peptide vaccine targeting PCSK9 has reduced LDL cholesterol and atherosclerotic plaque burden in mouse ...

In 2015, when the first cholesterol-lowering drugs targeting a protein called PCSK9 were about to hit the market, anticipation in the cardiovascular community ran high. Elevated levels of low-density ...

A draft report on the value-based price benchmark for the newly approved PCSK9 inhibitors for lowering bad cholesterol found that Repatha and Praluent should cost approximately 85% less than their ...

DelveInsight's PCSK9 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging PCSK9 ...

For those who play the high-stakes game of drug discovery, cholesterol-lowering PCSK9 inhibitors don’t seem anything like a sure bet. Patients will need to inject the drugs. They’re likely to be ...

Researchers have studied the association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with soluble P-selectin (sP-selectin) and their values in predicting major adverse cardiovascular ...